Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 211-220 of 525 results
Materials Today Bio, 2022 • October 15, 2022
This study focuses on developing a bionic multichannel nanofiber conduit loaded with Tubastatin A (TUBA) to promote spinal cord repair. The conduit is designed to act as a bridge, supporting nerve cell...
KEY FINDING: The Tubastatin A-loaded nanofibers exhibited a sustained-release profile, meaning the drug was released slowly over time, maintaining its activity and promoting axonal extension.
Inflammation and Regeneration, 2022 • December 1, 2022
This study investigated the effects of Quercetin (QCN) on motor function recovery in a rat model of brachial plexus avulsion (BPA) characterized by spinal ventral root avulsion/reimplantation and illu...
KEY FINDING: QCN significantly expedited motor function recovery in the forelimb, as shown by increased Terzis grooming test scores.
Pharmaceuticals, 2022 • December 19, 2022
This study explored the potential of Andrographolide (Andro) to alleviate post-operative pain in a rat model. The results showed that Andro, when administered via direct injection, significantly reduc...
KEY FINDING: Andro injections significantly reduced mechanical allodynia (pain from a stimulus that doesn't normally cause pain) compared to saline treatment.
Materials Today Bio, 2023 • January 1, 2023
This review explores the current use of functional nanomaterials for SCI treatment, categorizing them into inorganic, organic, and bioderived NPs based on their source composition. It examines the des...
KEY FINDING: Functional nanomaterials, ranging from 1 to 1000 nm, are categorized into inorganic, organic, and bioderived NPs, each with unique design and structural composition.
CNS Neuroscience & Therapeutics, 2023 • January 1, 2023
This study investigates the effects of Alpinetin on neuroinflammation and neuronal apoptosis following spinal cord injury (SCI). The research demonstrates that Alpinetin exerts antineuroinflammatory e...
KEY FINDING: Alpinetin inhibits microglia-mediated neuroinflammation and the activity of the JAK2/STAT3 pathway, both in vitro and in vivo.
Curr. Issues Mol. Biol., 2023 • February 16, 2023
This study investigates the molecular effects of hypoxic stress on neuronal cells chronically exposed to ethanol, using in vitro models to mimic spinal cord injury conditions in alcohol-consuming pati...
KEY FINDING: Long-term ethanol exposure has a cytotoxic effect on neuronal cells, inducing apoptosis.
Neurotrauma Reports, 2023 • January 1, 2023
The study investigated the anti-inflammatory effects of Etizolam (ETZ) administration after spinal cord injury (SCI) in mice. ETZ administration reduced the concentration of inflammatory cytokines in ...
KEY FINDING: Etizolam (ETZ) administration in the acute phase after spinal cord injury (SCI) reduced the concentration of inflammatory cytokines.
Materials Today Bio, 2023 • February 11, 2023
This review discusses the design principles of MNs for ISTR and their applications in promoting the repair of damaged tissues such as skin wounds, corneal injuries, myocardial infarction (MI), and end...
KEY FINDING: Microneedles can improve the delivery of active substances to enhance bioavailability in tissue repair.
J Control Release, 2023 • May 1, 2023
The study introduces an injectable hydrogel, Gel-Cur-M, loaded with curcumin micelles for treating chronic peripheral neuropathy in mice with chronic constriction injuries (CCI). Gel-Cur-M demonstrate...
KEY FINDING: The Gel-Cur-M exhibited superior functions compared to Gel and Cur-M alone, which includes ameliorating hyperalgesia while simultaneously improving locomotor and muscular functions after the nerve injury.
Toxins, 2023 • March 28, 2023
This study aimed to evaluate the therapeutic potential of Xeomin®, a commercial formulation of botulinum neurotoxin type A (BoNT/A), in a preclinical model of spinal cord injury (SCI) in mice. The res...
KEY FINDING: Xeomin® treatment resulted in significant amelioration of motor deficit in severe SCI mice starting from day 28 compared to saline-treated mice.